These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 7933084)

  • 1. A partially attenuated simian immunodeficiency virus induces host immunity that correlates with resistance to pathogenic virus challenge.
    Lohman BL; McChesney MB; Miller CJ; McGowan E; Joye SM; Van Rompay KK; Reay E; Antipa L; Pedersen NC; Marthas ML
    J Virol; 1994 Nov; 68(11):7021-9. PubMed ID: 7933084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunization of macaques with live simian human immunodeficiency virus (SHIV) vaccines conferred protection against AIDS induced by homologous and heterologous SHIVs and simian immunodeficiency virus.
    Kumar A; Mukherjee S; Shen J; Buch S; Li Z; Adany I; Liu Z; Zhuge W; Piatak M; Lifson J; McClure H; Narayan O
    Virology; 2002 Sep; 301(2):189-205. PubMed ID: 12359422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunization with a live, attenuated simian immunodeficiency virus (SIV) prevents early disease but not infection in rhesus macaques challenged with pathogenic SIV.
    Marthas ML; Sutjipto S; Higgins J; Lohman B; Torten J; Luciw PA; Marx PA; Pedersen NC
    J Virol; 1990 Aug; 64(8):3694-700. PubMed ID: 2164591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Temporal analyses of virus replication, immune responses, and efficacy in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine.
    Connor RI; Montefiori DC; Binley JM; Moore JP; Bonhoeffer S; Gettie A; Fenamore EA; Sheridan KE; Ho DD; Dailey PJ; Marx PA
    J Virol; 1998 Sep; 72(9):7501-9. PubMed ID: 9696847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Viral determinants of simian immunodeficiency virus (SIV) virulence in rhesus macaques assessed by using attenuated and pathogenic molecular clones of SIVmac.
    Marthas ML; Ramos RA; Lohman BL; Van Rompay KK; Unger RE; Miller CJ; Banapour B; Pedersen NC; Luciw PA
    J Virol; 1993 Oct; 67(10):6047-55. PubMed ID: 8371353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simian immunodeficiency virus (SIV) gag DNA-vaccinated rhesus monkeys develop secondary cytotoxic T-lymphocyte responses and control viral replication after pathogenic SIV infection.
    Egan MA; Charini WA; Kuroda MJ; Schmitz JE; Racz P; Tenner-Racz K; Manson K; Wyand M; Lifton MA; Nickerson CE; Fu T; Shiver JW; Letvin NL
    J Virol; 2000 Aug; 74(16):7485-95. PubMed ID: 10906202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD8+ lymphocyte antiviral activity in monkeys immunized with SIV recombinant poxvirus vaccines: potential role in vaccine efficacy.
    Leno M; Carter L; Venzon DJ; Romano J; Markham PD; Limbach K; Tartaglia J; Paoletti E; Benson J; Franchini G; Robert-Guroff M
    AIDS Res Hum Retroviruses; 1999 Mar; 15(5):461-70. PubMed ID: 10195756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccine-induced virus-neutralizing antibodies and cytotoxic T cells do not protect macaques from experimental infection with simian immunodeficiency virus SIVmac32H (J5).
    Hulskotte EG; Geretti AM; Siebelink KH; van Amerongen G; Cranage MP; Rud EW; Norley SG; de Vries P; Osterhaus AD
    J Virol; 1995 Oct; 69(10):6289-96. PubMed ID: 7666529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cellular immune response of rhesus monkeys infected with a partially attenuated nef deletion mutant of the simian immunodeficiency virus.
    Dittmer U; Nisslein T; Bodemer W; Petry H; Sauermann U; Stahl-Hennig C; Hunsmann G
    Virology; 1995 Oct; 212(2):392-7. PubMed ID: 7571408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cross-protective immune responses induced in rhesus macaques by immunization with attenuated macrophage-tropic simian immunodeficiency virus.
    Clements JE; Montelaro RC; Zink MC; Amedee AM; Miller S; Trichel AM; Jagerski B; Hauer D; Martin LN; Bohm RP
    J Virol; 1995 May; 69(5):2737-44. PubMed ID: 7707496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. With minimal systemic T-cell expansion, CD8+ T Cells mediate protection of rhesus macaques immunized with attenuated simian-human immunodeficiency virus SHIV89.6 from vaginal challenge with simian immunodeficiency virus.
    Genescà M; Skinner PJ; Hong JJ; Li J; Lu D; McChesney MB; Miller CJ
    J Virol; 2008 Nov; 82(22):11181-96. PubMed ID: 18787003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of vigorous cytotoxic T-lymphocyte responses by live attenuated simian immunodeficiency virus.
    Johnson RP; Glickman RL; Yang JQ; Kaur A; Dion JT; Mulligan MJ; Desrosiers RC
    J Virol; 1997 Oct; 71(10):7711-8. PubMed ID: 9311855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Administration of recombinant rhesus interleukin-12 during acute simian immunodeficiency virus (SIV) infection leads to decreased viral loads associated with prolonged survival in SIVmac251-infected rhesus macaques.
    Ansari AA; Mayne AE; Sundstrom JB; Bostik P; Grimm B; Altman JD; Villinger F
    J Virol; 2002 Feb; 76(4):1731-43. PubMed ID: 11799168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells.
    Quinnan GV; Yu XF; Lewis MG; Zhang PF; Sutter G; Silvera P; Dong M; Choudhary A; Sarkis PT; Bouma P; Zhang Z; Montefiori DC; Vancott TC; Broder CC
    J Virol; 2005 Mar; 79(6):3358-69. PubMed ID: 15731230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency.
    Pal R; Venzon D; Letvin NL; Santra S; Montefiori DC; Miller NR; Tryniszewska E; Lewis MG; VanCott TC; Hirsch V; Woodward R; Gibson A; Grace M; Dobratz E; Markham PD; Hel Z; Nacsa J; Klein M; Tartaglia J; Franchini G
    J Virol; 2002 Jan; 76(1):292-302. PubMed ID: 11739694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequential immunization of macaques with two differentially attenuated vaccines induced long-term virus-specific immune responses and conferred protection against AIDS caused by heterologous simian human immunodeficiency Virus (SHIV(89.6)P).
    Kumar A; Lifson JD; Li Z; Jia F; Mukherjee S; Adany I; Liu Z; Piatak M; Sheffer D; McClure HM; Narayan O
    Virology; 2001 Jan; 279(1):241-56. PubMed ID: 11145906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A single vaccination with attenuated SIVmac 239 via the tonsillar route confers partial protection against challenge with SIVmac 251 at a distant mucosal site, the rectum.
    Stahl-Hennig C; Eisenblatter M; Franz M; Stoiber H; Tenner-Racz K; Suh YS; Jasny E; Falkensammer B; Ugucchioni M; Georgsson G; Baroni C; Dierich MP; Lifson JD; Steinman RM; Uberla K; Racz P; Ignatius R
    Front Biosci; 2007 Jan; 12():2107-23. PubMed ID: 17127448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High beta-chemokine expression levels in lymphoid tissues of simian/human immunodeficiency virus 89.6-vaccinated rhesus macaques are associated with uncontrolled replication of simian immunodeficiency virus challenge inoculum.
    LaFranco-Scheuch L; Abel K; Makori N; Rothaeusler K; Miller CJ
    J Virol; 2004 Jun; 78(12):6399-408. PubMed ID: 15163733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolution of envelope-specific antibody responses in monkeys experimentally infected or immunized with simian immunodeficiency virus and its association with the development of protective immunity.
    Cole KS; Rowles JL; Jagerski BA; Murphey-Corb M; Unangst T; Clements JE; Robinson J; Wyand MS; Desrosiers RC; Montelaro RC
    J Virol; 1997 Jul; 71(7):5069-79. PubMed ID: 9188572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge.
    Buge SL; Richardson E; Alipanah S; Markham P; Cheng S; Kalyan N; Miller CJ; Lubeck M; Udem S; Eldridge J; Robert-Guroff M
    J Virol; 1997 Nov; 71(11):8531-41. PubMed ID: 9343211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.